pyrazines has been researched along with Androgen-Independent Prostatic Cancer in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butler, LM; Castillo, L; Centenera, MM; Daly, RJ; Grogan, J; Haynes, AM; Horvath, LG; Kench, JG; Lee, BY; Lin, HM; Shreeve, SM; Spielman, C; Stricker, PD; Yeung, NK | 1 |
| Barata, P; Cooney, M; Dreicer, R; Garcia, JA; Tyler, A; Wright, J | 1 |
| Kuna, M; Mikecin, AM; Raucher, D; Walker, LR | 1 |
| Franco, OE; Hayward, SW; Jin, R; Matusik, RJ; Wang, J; Wang, Y; Yamashita, H; Yu, X | 1 |
1 trial(s) available for pyrazines and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
Topics: Aged; Endothelial Cells; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrazines; Receptor, IGF Type 1; Receptors, Somatomedin | 2018 |
3 other study(ies) available for pyrazines and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Focal Adhesion Kinase 1; Humans; Immunoblotting; Immunohistochemistry; Male; Mice; Prostate; Prostatic Neoplasms, Castration-Resistant; Pyrazines; Sulfonamides; Xenograft Model Antitumor Assays | 2018 |
Thermally targeted p21 peptide enhances bortezomib cytotoxicity in androgen-independent prostate cancer cell lines.
Topics: Androgens; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Hot Temperature; Humans; Male; Molecular Mimicry; Peptides; Prostatic Neoplasms, Castration-Resistant; Protein Engineering; Pyrazines; Recombinant Fusion Proteins; Tumor Cells, Cultured | 2014 |
Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Male; NF-kappa B; Nitriles; Prostatic Neoplasms, Castration-Resistant; Pyrazines; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Xenograft Model Antitumor Assays | 2015 |